Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial.

Autor:	Park, Seung-Jung1 (AUTHOR) sjpark@amc.seoul.kr, Ahn, Jung-Min1 (AUTHOR), Kang, Do-Yoon1 (AUTHOR), Yun, Sung-Cheol2 (AUTHOR), Ahn, Young-Keun3 (AUTHOR), Kim, Won-Jang4 (AUTHOR), Nam, Chang-Wook5 (AUTHOR), Jeong, Jin-Ok6 (AUTHOR), Chae, In-Ho7 (AUTHOR), Shiomi, Hiroki8 (AUTHOR), Kao, Hsien-Li9 (AUTHOR), Hahn, Joo-Yong10 (AUTHOR), Her, Sung-Ho11 (AUTHOR), Lee, Bong-Ki12 (AUTHOR), Ahn, Tae Hoon13 (AUTHOR), Chang, Ki-Yuk14 (AUTHOR), Chae, Jei Keon15 (AUTHOR), Smyth, David16 (AUTHOR), Mintz, Gary S17 (AUTHOR), Stone, Gregg W18 (AUTHOR)
Zdroj:	Lancet. May2024, Vol. 403 Issue 10438, p1753-1765. 13p.
Databáze:	Business Source Ultimate
Externí odkaz:	Zobrazit plný text záznamu